Codelivery of TGFβ and Cox2 siRNA inhibits HCC by promoting T-cell penetration into the tumor and improves response to Immune Checkpoint Inhibitors
NAR Cancer · 09.01.2024 · 6 (1)
DOI: 10.1093/narcan/zcad059 ↗Kurz gefasst
Fachartikel in der Zeitschrift NAR Cancer, online erschienen am 09.01.2024. Verfasst von Wookhyun Kim und 12 weiteren Autor:innen. Beteiligte Einrichtung: Sirnaomics Inc., 20511 Seneca Meadows Parkway, Suite 200, Germantown, MD 20876, USA. Hauptthemen laut MEDLINE: Cyclooxygenase 2, Transforming Growth Factor beta, RNA, Small Interfering, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sirnaomics Inc.
Abstract (Originalsprache)
Upregulation of TGFβ and Cox2 in the tumor microenvironment results in blockade of T-cell penetration into the tumor. Without access to tumor antigens, the T-cell response will not benefit from administration of the immune checkpoint antibodies. We created an intravenous polypeptide nanoparticle that can deliver two siRNAs (silencing TGFβ and Cox2). Systemic administration in mice, bearing a syngeneic orthotopic hepatocellular carcinoma (HCC), delivers the siRNAs to various cells in the liver, and significantly reduces the tumor. At 2 mg/kg (BIW) the nanoparticle demonstrated a single agent action and induced tumor growth inhibition to undetectable levels after five doses. Reducing the siRNAs to 1mg/kg BIW demonstrated greater inhibition in the presence of PD-L1 mAbs. After only three doses BIW, we could still recover a smaller tumor and, in tumor sections, showed an increase in penetration of CD4+ and CD8+ T-cells deeper into the remaining tumor that was not evident in animals treated with non-silencing siRNA. The combination of TGFβ and Cox2 siRNA co-administered in a polypeptide nanoparticle can act as a novel therapeutic alone against HCC and may augment the activity of the immune checkpoint antibodies. Silencing TGFβ and Cox2 converts an immune excluded (cold) tumor into a T-cell inflamed (hot) tumor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Sirnaomics Inc., 20511 Seneca Meadows Parkway, Suite 200, Germantown, MD 20876, USA.
- Suzhou Sirnaomics Pharmaceuticals, Ltd., Biobay, Suzhou, China.
- National Taiwan University College of Medicine, No. 1, Section 1, Ren'ai Rd, Zhongzheng District, Taipei City 100, Taiwan.
ORCID-Profile: David M Evans
Förderung
- Sirnaomics Inc
Zitieren
APA
Kim, W., Ye, Z., Simonenko, V., Shahi, A., Malikzay, A., Long, S. Z., Xu, J. J., Lu, A., Horng, J. H., Wu, C. R., Chen, P. J., Lu, P. Y., & Evans, D. M. (2024). Codelivery of TGFβ and Cox2 siRNA inhibits HCC by promoting T-cell penetration into the tumor and improves response to Immune Checkpoint Inhibitors. NAR Cancer, 6(1). https://doi.org/10.1093/narcan/zcad059
Vancouver
Kim W, Ye Z, Simonenko V, Shahi A, Malikzay A, Long SZ, et al. Codelivery of TGFβ and Cox2 siRNA inhibits HCC by promoting T-cell penetration into the tumor and improves response to Immune Checkpoint Inhibitors. NAR Cancer. 2024;6(1). doi:10.1093/narcan/zcad059
BibTeX
@article{Kim2024,
author = {Kim, Wookhyun and Ye, Zhou and Simonenko, Vera and Shahi, Aashirwad and Malikzay, Asra and Long, Steven Z and Xu, John J and Lu, Alan and Horng, Jau-Hau and Wu, Chang-Ru and Chen, Pei-Jer and Lu, Patrick Y and Evans, David M},
title = {Codelivery of TGFβ and Cox2 siRNA inhibits HCC by promoting T-cell penetration into the tumor and improves response to Immune Checkpoint Inhibitors},
journal = {NAR Cancer},
year = {2024},
volume = {6},
number = {1},
doi = {10.1093/narcan/zcad059}
}
EUVIMED